Momenta Pharmaceuticals announced that after a strategic review of its operations, the company will refocus on novel therapeutics rather than on biosimilars.
Yesterday, Momenta Pharmaceuticals announced that after a strategic review of its operations, the company will refocus on novel therapeutics rather than on biosimilars.
Momenta says that its 5-year restructuring plan, which involves layoffs of 50% of its staff—or 110 workers—will produce approximately $250 million in savings, but it adds that it will need to conduct additional fundraising activities in the coming years.
Read more about Momenta and its biosimilars.
Momenta noted that it will continue to develop 2 of its late-stage biosimilars: M923, Momenta’s wholly owned proposed adalimumab biosimilar referencing Humira, and M710, a proposed aflibercept biosimilar referencing Eylea.
The aflibercept candidate is being developed in conjunction with Mylan, and the partnership had announced in January 2018 that it would enter a pivotal clinical trial of the drug in patients with diabetic macular edema.
Mylan also partnered with Momenta on 5 additional biosimilar products, including an abatacept (Orencia) candidate for which the companies have completed a phase 1 study that failed to meet its primary pharmacokinetic end points, and 4 undisclosed biosimilar candidates in preclinical development. Momenta indicated that it is discussing the future of these products with Mylan.
When Mylan and Momenta first announced their partnership in early 2017, the deal was expected to generate up to $245 million for Momenta, based on milestone payments tied to achievements. At the time, the companies expected to submit the adalimumab product for regulatory approval in 2017, with a commercial launch planned for 2018.
Momenta’s unreached biosimilar goals and its subsequent change of course raise questions about the sustainability of biosimilar development for smaller companies. With high development costs, an uncertain patent landscape, and sluggish biosimilar uptake in the United States, it remains to be seen whether smaller ventures, even in partnership with more established companies, will be able to make their biosimilar efforts financially feasible.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.